Chemoradiotherapy News and Research

RSS

Chemoradiotherapy is a treatment that combines chemotherapy with radiation therapy. Also called chemoradiation.

Tracking circulating tumor DNA could indicate gastroesophageal cancer treatment response

Monitoring levels of DNA shed by tumors and circulating in the bloodstream could help doctors accurately assess how gastroesophageal cancers are responding to treatment, and potentially predict future prognosis, suggests a new study led by researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

19 Mar 2024

Innovative CAR T cell therapy targets two proteins to combat aggressive brain tumor growth

Breakthrough in Brain Cancer Treatment: Dual-Target CAR T Cell Therapy Shows Promise in Early Clinical Trial.

15 Mar 2024

Researchers announce a new genetic classification system for gastric cancer

Professor Sang Cheul Oh of the Division of Oncology/Hematology, Department of Internal Medicine, Korea University College of Medicine, Professor Sang‑Hee Kang of the Department of Surgery, Korea University's Guro Hospital, and Professor Sun Young Yim of the Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine announced a new genetic classification system for gastric cancer by a multicenter study with the University of Texas MD Anderson Cancer Center.

6 Nov 2023

Anti-anxiety drug can improve the effectiveness of chemo-radiotherapy towards glioblastoma

A new research study shows that cerebrospinal fluid reduces current treatment efficacy in brain cancer and identifies new therapeutic opportunities.

25 Oct 2023

Perioperative durvalumab may change standard-of-care for patients with resectable lung cancer

A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to results of a Phase III trial reported by researchers at The University of Texas MD Anderson Cancer Center.

24 Oct 2023

Researchers discover how a sugar molecule can affect cancer cell response to chemoradiotherapy

Researchers at Georgetown University's Lombardi Comprehensive Cancer Center and colleagues who have been exploring the complexities of biochemical pathways involved in cancer development have found that a form of glucose, a type of sugar, is intricately linked to a pathway used to build DNA molecules.

12 Jun 2023

Patient-derived head and neck cancer organoids could aid the discovery of novel therapies

Researchers from the Organoid group (Hubrecht Institute) and UMC Utrecht have developed a biobank with organoids derived from patients with head and neck cancer (HNC).

12 May 2023

Pre- and post-surgical immunotherapy-based treatment significantly improved lung cancer outcomes

A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to Phase III trial results presented today by researchers from The University of Texas MD Anderson Cancer Center at the American Association for Cancer Research (AACR) Annual Meeting 2023.

17 Apr 2023

Pathologic complete response can be used as a prognostic factor for clinical outcomes in soft tissue sarcoma patients

Combined long-term survival results from nonrandomized phase II trial NRG Oncology RTOG 0630 and the ancillary analysis of the combined NRG-RTOG 0630/9514 trials indicate that pathologic complete response (pCR) is associated with improved survival outcomes for patients with localized soft tissue sarcoma (STS) who receive preoperative chemoradiotherapy or radiotherapy.

31 Mar 2023

Treatment to boost white blood cells may benefit patients with glioblastoma

A new study led by Washington University School of Medicine in St. Louis reveals at least one cause of low white blood cell counts in patients treated for glioblastoma and demonstrates a potential treatment strategy that improves survival in mice.

27 Jan 2023

FDA-approved anti-sedative could alleviate common side effects of cancer treatments

Researchers in China have discovered that inhibiting a protein called the GABAA receptor can protect intestinal stem cells from the toxic effects of chemotherapy and radiotherapy.

20 Sep 2022

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

Researchers from Japan today reported that the first phase II study to evaluate the efficacy and safety of durvalumab and concurrent curative radiation therapy for PD-L1-positive unresectable locally advanced non-small cell lung cancer without chemotherapy met its primary endpoint with tolerable adverse reactions.

8 Aug 2022

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non-small cell lung cancer without disease progression after either concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy (sCRT), according to findings presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

8 Aug 2022

Clinical trial examining the combination of atezolizumab and chemoradiation for patients with limited-stage SCLC reaches accrual

The NRG Oncology/Alliance clinical trial NRG-LU005, examining the addition of the immunotherapy drug atezolizumab combined with chemoradiation for patients with limited-stage small cell lung cancer (SCLC) recently reached the trial's accrual goal of 506 patients.

8 Jul 2022

Immunotherapy combined with chemoradiation and surgery could help treat nonmetastatic gastroesophageal cancer

Immunotherapy has transformed treatment for patients with stage 4 metastatic esophageal and gastric cancers. In patients with these malignancies, immunotherapy has been shown to prolong survival when patients' tumors exhibit a high expression of an immune-related protein called PD-L1.

16 May 2022

Trial shows safety and immunogenicity of immunotherapy with chemoradiation in cervical cancer patients

A Phase I/Ib trial conducted by the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group NRG Oncology, NRG-GY017, concluded that the addition of the immunotherapy drug atezolizumab prior to and concurrently given with chemoradiation (CRT) treatment was safe for women with node-positive, locally advanced cervical cancer.

19 Mar 2022

Indication of minor added benefit of nivolumab for adjuvant treatment of esophageal cancer

In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care investigated whether nivolumab has an added benefit over watchful waiting in the adjuvant treatment of adults with carcinoma of the esophagus or the gastroesophageal junction and pathological residual disease after prior neoadjuvant chemoradiotherapy (CRT).

10 Dec 2021

Chromosome aberrations linked to acute toxicities in esophageal cancer patients

Japanese researchers identified chromosome aberrations as a new biomarker in predicting an esophageal cancer patient's risk of experiencing severe chemoradiotherapy side effects.

28 Oct 2021

Investigational Oncomagnetic Device shrinks end-stage recurrent glioblastoma

Houston Methodist Neurological Institute researchers from the department of neurosurgery shrunk a deadly glioblastoma tumor by more than a third using a helmet generating a noninvasive oscillating magnetic field that the patient wore on his head while administering the therapy in his own home.

22 Jul 2021

Older patients often do not receive optimal therapy for esophageal cancers due to perceived risks

Elderly patients (70 years and over) with locally advanced esophageal (E) and esophagogastric junction (EGJ) cancer (located in the stomach and esophagus) should be considered for optimal therapy that has the potential to cure.

9 Feb 2021